---
title: "VK2735 in Chronic weight management: Economic burden and healthcare resource utilization"
description: "Formulary evidence on VK2735 in Chronic weight management: Economic burden and healthcare resource utilization. Topics: Excess annual medical expenditures associated with obesity in U.S. adults, Causal estimate of medical costs due to obesity by payer and obesity class, Annual health care expenditures by BMI class in U.S. national survey data, Work loss and indirect costs to employers by BMI class, and 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### Excess annual medical expenditures associated with obesity in U.S. adults

> “Over 30 units of BMI, each one-unit BMI increase was associated with an additional cost of $253 (95% CI $167-$347) per person. Among adults, obesity was associated with $1,861 (95% CI $1,656-$2,053) excess annual medical costs per person, accounting for $172.74 billion (95% CI $153.70-$190.61) of annual expenditures. Severe obesity was associated with excess costs of $3,097 (95% CI $2,777-$3,413) per adult.”
> “We estimated continuous BMI-related health care expenditures using data from the Medical Expenditure Panel Survey (MEPS) 2011–2016 for 175,726 respondents.”
> “Costs are reported in $US 2019.”

Source: [Ward et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7990296/)

<a id="topic-2.2.1.8.2-2"></a>

### Causal estimate of medical costs due to obesity by payer and obesity class

> “Adults with obesity in the United States compared with those with normal weight experienced higher annual medical care costs by $2,505 or 100%, with costs increasing significantly with class of obesity, from 68.4% for class 1 to 233.6% for class 3. The effects of obesity raised costs in every category of care: inpatient, outpatient, and prescription drugs. Increases in medical expenditures due to obesity were higher for adults covered by public health insurance programs ($2,868) than for those having private health insurance ($2,058). In 2016, the aggregate medical cost due to obesity among adults in the United States was $260.6 billion.”
> “The expenditure estimates were obtained from 2-part models of instrumental variables in which the respondent’s body mass index (BMI) was instrumented using the BMI of their biological child.”

Source: [Cawley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10394178/)

<a id="topic-2.2.1.8.2-3"></a>

### Annual health care expenditures by BMI class in U.S. national survey data

> “Healthcare expenditures, adjusted to the 2019 consumer price index, significantly increased with increasing BMI category (Table 2). The average total annual expenditures among respondents with C3 obesity were 60% higher than for NW respondents ($9212 vs. $5,236, respectively; p < 0.001). Also, the average annual prescription drug expenditures were more than double for respondents with C3 obesity compared to NW respondents ($2954 vs. $1,232, respectively; p < 0.001). Annual expenditures were driven largely by inpatient and pharmacy costs, which increased with increasing BMI (Table 2).”
> “Compared to NW respondents (1.71 days per 6 months), the respondents in all the other BMI categories missed significantly more days of work due to illness or injury (OW: 2.30; C1: 2.47; C2: 2.66, C3: 2.92 days per 6 months; p < 0.001).”

Source: [MacEwan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10804324/)

<a id="topic-2.2.1.8.2-4"></a>

### Work loss and indirect costs to employers by BMI class

> “719,482 employees (normal weight: 106,631, overweight: 230,637, obesity class 1: 185,850, obesity class 2: 101,909, obesity class 3: 94,455) were included. Outcomes increased with each higher BMI category for the mean number of absence hours ([in order of BMI category]: 262, 273, 285, 290, 304) and percentage of employees with a claim (STD: 6.8%, 7.6%, 9.7%, 11.7%, 17.0%; LTD: 0.4%, 0.4%, 0.5%, 0.6%, 0.8%; WC: 2.7%, 2.8%, 3.4%, 3.6%, 3.5%). Estimated costs to the employer associated with absenteeism, STD, LTD, and WC were $1,036, $611, $38, and $95 higher per year (respectively) in the obesity class 3 cohort relative to the normal weight cohort.”

Source: [Shinde et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11229424/)

<a id="topic-2.2.1.8.2-5"></a>

### Estimated reduction in health care spending with weight loss

> “Overall, adults with employer-sponsored insurance with a weight loss of 5% were estimated to spend a mean of $670 (95% CI, $654-$686) less on health care (8% less), and those with a weight loss of 25% spent an estimated mean of $2849 (95% CI, $2783-$2916) less on health care (34% less). Among adults with Medicare who had 1 or more comorbid conditions, a 5% weight loss was estimated to reduce spending by $1262 (95% CI, $1217-$1306) (7% less) and a 25% weight loss was estimated to reduce health care spending by a mean of $5442 (95% CI, $5254-$5629) (31% less).”

Source: [Thorpe and Joski (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11621981/)

<a id="topic-2.2.1.8.2-6"></a>

### Global economic impact of overweight and obesity

> “The economic impact of OAO in 2019 is estimated at 2.19% of global gross domestic product (GDP) ranging on average from US$20 per capita in Africa to US$872 per capita in the Americas and from US$6 in low-income countries to US$1110 in HICs.”
> “If current trends continue, by 2060, the economic impacts from OAO are projected to rise to 3.29% of GDP globally.”

Source: [Okunogbe et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9494015/)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
